Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of CL2018002114A1publicationCriticalpatent/CL2018002114A1/en
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
LA INVENCIÓN PROPORCIONA COMPUESTOS DE LA FÓRMULA (1), COMO SE DESCRIBE EN EL PRESENTE DOCUMENTO, JUNTO CON LAS SALES FARMACÉUTICAMENTE ACEPTABLES, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES COMPUESTOS, Y MÉTODOS PARA UTILIZAR ESTOS COMPUESTOS, SALES Y COMPOSICIONES PARA TRATAR INFECCIONES VIRALES, PARTICULARMENTE INFECCIONES CAUSADAS POR EL VIRUS DE LA HEPATITIS B, Y LA REDUCCIÓN DE LA APARICIÓN DE ENFERMEDADES GRAVES ASOCIADAS CON VHB.THE INVENTION PROVIDES COMPOUNDS OF THE FORMULA (1), AS DESCRIBED IN THIS DOCUMENT, TOGETHER WITH THE PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS FOR USING THESE COMPOSITIONS, COMPOSTITION COMPARTMENTS CAUSED BY THE VIRUS OF HEPATITIS B, AND THE REDUCTION OF THE APPEARANCE OF SERIOUS ILLNESSES ASSOCIATED WITH HBV.
CL2018002114A2016-02-192018-08-06
Tetracyclic pyridone compounds as antivirals
CL2018002114A1
(en)